Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Diabetic kidney disease (DKD) still lacks therapies that reverse or halt progression of structural kidney injury at early albuminuric stages. Extending our recent study published in Kidney International that identified narciclasine (Ncls) through a patient-derived transcriptomic approach and validated kidney protection across renal fibrosis models, we conducted a preclinical drug evaluation in db/db mice with early DKD, assessing renal protection and effects on obesity-related metabolic phenotypes.
Male db/db mice received oral Ncls or vehicle beginning at 10 weeks of age, when obesity and albuminuria were evident. Treatment continued for 10 weeks. We prospectively tracked body weight, urinary albumin (albuminuria), serum total cholesterol, glucose, and liver enzymes (ALT/AST). At the study end, kidneys were assessed by PAS staining (glomerular hypertrophy, mesangial matrix expansion, glomerulosclerosis) and immunohistochemistry for F4/80+ macrophages. Outcomes were compared with age-matched vehicle controls.
By week 12 (two weeks after initiation), Ncls reversed the upward trajectories of body weight and albuminuria; both declined consistently through week 20. At endpoint, Ncls markedly attenuated glomerular hypertrophy, mesangial expansion, and glomerulosclerosis on PAS, and reduced interstitial F4/80+ macrophage area. Systemically, Ncls significantly lowered serum total cholesterol and improved hepatic indices (reduced ALT/AST), whereas serum glucose remained unchanged. Together, these data indicate parallel improvement of renal structural/proteinuric readouts and obesity-related metabolic phenotypes.
Ncls yields glycemia-independent improvements in early diabetic kidney injury in db/db mice， reducing albuminuria and glomerular pathology while concurrently improving body weight, cholesterol, and liver enzymes. These findings nominate Ncls as a kidney-protective candidate and support preclinical optimization and combination strategies alongside current standard therapies for DKD.
